This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2016 Mar 15;315(11):1107-8.

doi: 10.1001/jama.2016.2240.

Biomarkers and Surrogate Endpoints: Developing Common Terminology and Definitions

Melissa A Robb¹, Pamela M McInnes², Robert M Califf³

Affiliations

Affiliations

¹ Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
² National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland.
³ US Food and Drug Administration, Silver Spring, Maryland.

PMID: 26978201
DOI: 10.1001/jama.2016.2240

Biomarkers and Surrogate Endpoints: Developing Common Terminology and Definitions

Melissa A Robb et al. JAMA. 2016.

. 2016 Mar 15;315(11):1107-8.

doi: 10.1001/jama.2016.2240.

Authors

Melissa A Robb¹, Pamela M McInnes², Robert M Califf³

Affiliations

¹ Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
² National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland.
³ US Food and Drug Administration, Silver Spring, Maryland.

PMID: 26978201
DOI: 10.1001/jama.2016.2240

No abstract available

PubMed Disclaimer

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations